Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Assessment of Change in Atherosclerotic Plaque by Serial CCTA
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 400
- Registration Number
- NCT03414840
- Locations
- 🇰🇷
Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 69
- Registration Number
- NCT03415178
- Locations
- 🇺🇸
Investigational Site Number 8400022, Summerville, South Carolina, United States
🇺🇸Investigational Site Number 8400017, Jacksonville, Florida, United States
🇺🇸Investigational Site Number 8400013, Ponte Vedra, Florida, United States
Statins and CPAP in Adipose Tissue of OSA
- Conditions
- Interventions
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT03308578
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 96
- Registration Number
- NCT03289429
- Locations
- 🇪🇬
Assiut University, Assiut, Egypt
Comparison of Lipophilic Versus Hydrophilic Statins on Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 85
- Registration Number
- NCT03255044
- Locations
- 🇪🇬
Ain Shams University Hospital Cardiology Rehab Unit, Cairo, Egypt
Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 112
- Registration Number
- NCT03186404
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Effects of Atorvastatin in Graves' Orbitopathy (GO)
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 88
- Registration Number
- NCT03110848
- Locations
- 🇮🇹
Ospedale Cisanello-Endocrinology I and II, Pisa, Italy
Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Korea University Guro Hospital
- Target Recruit Count
- 10001
- Registration Number
- NCT03073863
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
- Conditions
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Loyola University
- Registration Number
- NCT03066466
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Yuejin Yang
- Target Recruit Count
- 124
- Registration Number
- NCT03047772
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.